p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours

被引:9
作者
Daidone, MG
Benini, E
Valentinis, B
Bolis, G
Villa, A
Silvestrini, R
机构
[1] IST NAZL STUDIO & CURA TUMORI,I-20133 MILAN,ITALY
[2] UNIV MILAN,CLIN OSTET GINECOL 1,MILAN,ITALY
关键词
interlesional heterogeneity; ovarian surface epithelial-stromal tumour; ploidy; proliferative activity; P53; synchronous lesions;
D O I
10.1016/0959-8049(96)00101-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to investigate biological heterogeneity between primary and metastatic ovarian cancer lesions from individual patients as a means of elucidating steps in clinical progression. Cancer tissue from 61 untreated patients with ovarian surface epithelial-stromal tumours was examined. p53 expression detected immunocytochemically by the PAb1801 antibody, DNA content evaluated by flow cytometry, and cell proliferation evaluated as the [H-3]thymidine labelling index were investigated in primary tumours and corresponding synchronous metastases. The frequency of p53 positivity was similar in primary (62%) and metastatic (66%) sites, with an agreement between the two lesions from the same patient in 97% of the cases. Similarly, aneuploidy frequency (80%) and DNA indices were superimposable in primary and metastatic lesions from the same patient, with a 94% agreement. The frequency of aneuploidy was higher in p53-positive than in p53-negative lesions. An overall poor agreement (r(s) = 0.44) was observed for proliferative activity of primary and metastatic lesions, due to a heterogeneous profile in omental with respect to primary tumours, which was mainly evident in p53-positive cancers. Conversely, cell proliferation of peritoneal, abdominal and pelvic lesions was qualitatively similar to that of the primary tumour in 88% of patients. Copyright (C) 1996 Elsevier Science Ltd
引用
收藏
页码:1388 / 1393
页数:6
相关论文
共 40 条
[1]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[2]  
AYHAN A, 1992, INT J ONCOL, V1, P431
[3]   IMMUNOCHEMICAL ANALYSIS OF THE P53 ONCOPROTEIN IN MATCHED PRIMARY AND METASTATIC HUMAN TUMORS [J].
BARTKOVA, J ;
BARTEK, J ;
VOJTESEK, B ;
LUKAS, J ;
REJTHAR, A ;
KOVARIK, J ;
MILLIS, RR ;
LANE, DP ;
BARNES, DM .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (06) :881-886
[4]   CLINICAL-SIGNIFICANCE OF ONCOGENES AND GROWTH-FACTORS IN OVARIAN CARCINOMAS [J].
BAUKNECHT, T ;
BIRMELIN, G ;
KOMMOSS, F .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1990, 37 (06) :855-862
[5]   P53 ACCUMULATION IN OVARIAN CARCINOMAS AND ITS PROGNOSTIC IMPLICATIONS [J].
BOSARI, S ;
VIALE, G ;
RADAELLI, U ;
BOSSI, P ;
BONOLDI, E ;
COGGI, G .
HUMAN PATHOLOGY, 1993, 24 (11) :1175-1179
[6]   GENE AMPLIFICATION AND TUMOR PROGRESSION [J].
BRISON, O .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1155 (01) :25-41
[7]   TUMORIGENESIS ASSOCIATED WITH THE P53 TUMOR-SUPPRESSOR GENE [J].
CHANG, F ;
SYRJANEN, S ;
TERVAHAUTA, A ;
SYRJANEN, K .
BRITISH JOURNAL OF CANCER, 1993, 68 (04) :653-661
[8]  
CONTE PF, 1989, CANCER, V64, P1188, DOI 10.1002/1097-0142(19890915)64:6<1188::AID-CNCR2820640604>3.0.CO
[9]  
2-5
[10]   P53 GENE POINT MUTATIONS IN RELATION TO P53 NUCLEAR-PROTEIN ACCUMULATION IN COLORECTAL CANCERS [J].
COSTA, A ;
MARASCA, R ;
VALENTINIS, B ;
SAVARINO, M ;
FARANDA, A ;
SILVESTRINI, R ;
TORELLI, G .
JOURNAL OF PATHOLOGY, 1995, 176 (01) :45-53